

Amendments to the Claims


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claim 1. (Currently amended) A method for the treatment of diabetes type comprising administering to a warm-blooded animal a pharmaceutical composition consisting essentially of an effective amount of a renin inhibitor or a pharmaceutically acceptable salt thereof.


2. (Withdrawn) A method of aiding plaque stabilization comprising administering to a warm-blooded animal an effective amount of a renin inhibitor or a pharmaceutically acceptable salt thereof.

3. (Original) The method of Claim 1, wherein the renin inhibitor is a compound of formula (I)



or a pharmaceutically acceptable salt thereof.

4. (Withdrawn) The method of Claim 2, wherein the renin inhibitor is a compound of formula (I)



or a pharmaceutically acceptable salt thereof.

5. (Withdrawn) A pharmaceutical composition comprising a renin inhibitor in combination and at least one additional active agent selected from the group consisting of:

- (i) an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof;
- (ii) ACE inhibitor or a pharmaceutically acceptable salt thereof;
- (iii) CCB or a pharmaceutically acceptable salt thereof;
- (iv) HMG-Co-A reductase inhibitor or a pharmaceutically acceptable salt thereof;
- (v) aldosterone synthase inhibitor or a pharmaceutically acceptable salt thereof;
- (vi) aldosterone antagonist or a pharmaceutically acceptable salt thereof;
- (vii) dual ACE/NEP inhibitor or a pharmaceutically acceptable salt thereof;
- (viii) β -blocker or a pharmaceutically acceptable salt thereof;
- (ix) endothelin antagonist or a pharmaceutically acceptable salt thereof;
- (x) diuretic or a pharmaceutically acceptable salt thereof;
- (xi) oral hypoglycaemic agent or a pharmaceutically acceptable salt thereof;
- (xii) Mrp2 inhibitor;
- (xiii) furosemide or a pharmaceutically acceptable salt thereof; and
- (xiv) Gleevec or a pharmaceutically acceptable salt thereof.

6. (Withdrawn) The pharmaceutical composition of Claim 5, wherein the rennin inhibitor is a compound of formula (I) or a pharmaceutically acceptable salt thereof.
7. (Withdrawn) A method for the prevention of, delay progression to overt to or treatment of a condition or disease selected from:
 - (a) diabetes type 2 (associated with or without hypertension);
 - (b) severe hypertension, PH, malignant hypertension, isolated systolic hypertension and familial dyslipidemic hypertension;
 - (c) endothelial dysfunction (with or without hypertension);
 - (d) survival post-MI, increase of formation of collagen and coarctation of aorta;
 - (e) restenosis after percutaneous transluminal angioplasty
 - (f) PVD, including PAD and peripheral venous disorders;
 - (g) CAD;
 - (h) morbidity and mortality;
 - (i) cerebrovascular diseases;
 - (j) metabolic disorder (Syndrome X);
 - (k) AF;
 - (l) organ protection;
 - (m) renoprotection;
 - (n) renal failure, e.g., chronic renal failure;
 - (o) glomerulonephritis (may be associated with the nephritic syndrome, a high blood pressure and a decreased renal function), focal, segmental glomerulonephritis and minimal change nephropathy;
 - (p) nephrotic syndrome and renal fibrosis;
 - (q) AIN, ATN and acute tubulo-inerstitial nephritis;
 - (r) end-stage renal disease (ESRD);
 - (s) PKD;


- (t) vascular inflammation;
- (u) obesity;
- (v) migraine headaches
- (w) renin secreting tumors; and
- (x) vasculitides,

comprising administering to a warm-blooded animal an effective amount of the pharmaceutical composition of Claim 5.

8. (Withdrawn) The method of Claim 7, wherein the rennin inhibitor is a compound of formula (I) or a pharmaceutically acceptable salt thereof.

9. (Withdrawn) A method of aiding plaque stabilization comprising administering to a warm-blooded animal an effective amount of the pharmaceutical composition of Claim 5.

10. (Withdrawn) The method of Claim 9, wherein the rennin inhibitor is a compound of formula (I)



or a pharmaceutically acceptable salt thereof.

11-12. (Canceled)]